Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.
It is shown that AML1 point mutation is one of the major driving forces of MDS/AML, and these mutations may represent a distinct clinicopathologic-genetic entity. Expand
The Incidence of Leukemia, Lymphoma and Multiple Myeloma among Atomic Bomb Survivors: 1950–2001
Analysis of radiation effects on leukemia, lymphoma and multiple myeloma incidence in the Life Span Study cohort of atomic bomb survivors updated 14 years since the last comprehensive report on these malignancies found that ERR models can often provide equivalent and sometimes more parsimonious descriptions of the excess risk than EAR models. Expand
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
- H. Gatanaga, T. Hayashida, +17 authors S. Oka
- Clinical infectious diseases : an official…
- 1 November 2007
Genotype-based EFV dose reduction is feasible in CYP2B6 *6 /*6 and *6/*26 carriers, which can reduce EFV-associated CNS symptoms, and CNS-related symptoms improved with dose reduction in 10 of the 14 patients, although some had not been aware of the symptoms at initial dosage. Expand
Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia.
The results suggest that AML1 point mutations are related to low-dose radiation or alkylating agents and play a role distinct from that of leukemogenic chimeras as a result of chromosomal translocations caused by sublethal radiation or topoisomerase II inhibitors. Expand
Establishment and characterization of a novel imatinib‐sensitive chronic myeloid leukemia cell line MYL, and an imatinib‐resistant subline MYL‐R showing overexpression of Lyn
Lyn may play an important role in imatinib‐resistance in MYL‐R, and some novel reagents, including siRNA targeting Lyn, may have good potential to overcome this resistance. Expand
Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation.
- O. Katoh, H. Tauchi, K. Kawaishi, A. Kimura, Y. Satow
- Biology, Medicine
- Cancer research
- 1 December 1995
The expression of the KDR gene transcript is demonstrated, which encodes a cell surface receptor for VEGF, in normal human hematopoietic stem cells, megakaryocytes, and platelets as well as in human leukemia cell lines, HEL and CMK86, suggesting that V EGF may give leukemia cells some abilities of resistance against radiotherapy in an autocrine or paracrine manner. Expand
Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan.
A randomized study to elucidate whether addition of granulocyte colony-stimulating factor (G-CSF) to immunosuppressive therapy is valuable for the treatment of severe aplastic anemia (SAA) in adults found no differences between the groups in terms of the incidence of infections and febrile episodes. Expand
Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations
MDS/AML arising from AML1/RUNX1 mutations has a significant association with −7/7q- alteration, and frequently involves RTK–RAS signaling pathway activation. Expand
c‐kit point mutation of extracellular domain in patients with myeloproliferative disorders
- Y. Nakata, A. Kimura, +5 authors Y. Satow
- Biology, Medicine
- British journal of haematology
- 1 November 1995
To the first report with a c‐kit point mutation found in human fresh tumour cells, the same point mutations at codon 52 causing amino acid substitution (Asp → Asn) are revealed. Expand
Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis.
The expression of Bmi-1, which is required to regulate the self-renewal in CD34+ cells from 51 patients with cases of MDS and acute myeloid leukemia preceded by MDS, is proposed as a novel molecular marker to predict the progression and prognosis of M DS. Expand